dr. saunthararajah on mechanisms of resistance to 5-azacytidine/decitabine in mds-aml
Published 8 years ago • 1K plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
7:49
mechanisms of resistance to 5-azacytidine/decitabine in mds-aml
-
2:40
safety and efficacy of sabatolimab plus azacitidine or decitabine in patients with hr-mds and aml
-
1:22
dr. daver on updated findings with magrolimab/azacitidine in mds
-
1:49
dr. daver on results of a combination study with azacitidine/nivolumab in aml
-
1:09
dr. daver on the rationale of azacitidine and nivolumab in acute myeloid leukemia
-
3:03
venetoclax and 5-azacytidine for the treatment of mds and cmml
-
1:48
dr. ravandi on resistance in aml
-
19:18
understanding efficacy of azacitidine in different mds subgroups
-
8:13
introduction: treatment landscape of mds
-
6:47
treatment of myelodysplastic syndromes refractory to hypomethylating agent
-
5:36
david sallman: magrolimab plus azacitidine effective in mds and aml
-
1:25
trial to evaluate eprenetapopt-azacytidine combo in tp53 mds completes enrollment
-
2:09
dr. sekeres on combination therapies with azacitidine in cmml and mds
-
53:29
autoimmune disorders and mds
-
1:48
tp53-mutant aml linked to poorer outcomes with decitabine plus venetoclax
-
3:34
anti-cd47 antibodies & azacitidine for aml and mds
-
2:02
what are hypomethylating agents and when are they used for mds?
-
0:53
dr. dinardo on rationale to combine enasidenib and azacitidine in aml
-
1:24
antibodies for the treatment of mds: magrolimab & sabatolimab